SpringerLink
Log in

Management of Hypercholesterolemia in Children

  • Current Opinion
  • Published:
Pediatric Drugs Aims and scope Submit manuscript

Abstract

Cardiovascular disease (CVD) remains the leading cause of death and morbidity in our society. One of the major risk factors for CVD is hypercholesterolemia. Hypercholesterolemia in children can be caused by a hereditary disorder or can be secondary to other diseases or drugs. In order to prevent CVD later in life, children with hypercholesterolemia should be identified and treated as early as possible. Currently, several different screening strategies have been developed, using either universal screening or case finding to search for children at risk. Once those children are identified, the first step in treatment is lifestyle adjustment. If cholesterol levels remain elevated, the drugs of first choice are statins. Other pharmacological options are ezetimibe or bile acid sequestrants. These agents have all proven to be safe and effective in lowering low-density lipoprotein cholesterol levels and improving surrogate markers of CVD. However, there is a need for long-term follow-up studies to answer the question as to whether it is safe to initiate treatment at a young age to prevent CVD later in life.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Germany)

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. McNamara JJ, Molot MA, Stremple JF, Cutting RT. Coronary artery disease in combat casualties in Vietnam. JAMA. 1971;17(216):1185–7.

    Article  Google Scholar 

  2. Berenson G, Srinivasan S. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. N Engl J Med. 1998;338:1650–6.

    Article  CAS  PubMed  Google Scholar 

  3. Relationship of atherosclerosis in young men to serum lipoprotein cholesterol concentrations and smoking. A preliminary report from the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. JAMA. 1990;264:3018–24.

    Google Scholar 

  4. Wiegman A, de Groot E, Hutten BA, Rodenburg J, Gort J, Bakker HD, et al. Arterial intima-media thickness in children heterozygous for familial hypercholesterolaemia. Lancet. 2004;31(363):369–70.

    Article  Google Scholar 

  5. De Jongh S, Lilien MR, op’t Roodt J, Stroes ESG, Bakker HD, Kastelein JJP. Early statin therapy restores endothelial function in children with familial hypercholesterolemia. J Am Coll Cardiol. 2002;40:2117–21.

    Google Scholar 

  6. Goldstein JL, Hobbs HH, Brown MS. Part 12: Lipids chapter 120: familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular bases of inherited disease. 8th ed. New York: McGraw-Hill; 2001. pp. 2863–913.

  7. Innerarity TL, Weisgraber KH, Arnold KAYS, Mahley RW, Kraussf RM, Vega GL, et al. Familial defective apolipoprotein B-100: low density lipoproteins with abnormal receptor binding. Proc Natl Acad Sci USA. 1987;84:6919–23.

    Google Scholar 

  8. Abifadel M, Rabès J-P, Devillers M, Munnich A, Erlich D, Junien C, et al. Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease. Hum Mutat. 2009;30:520–9.

    Article  CAS  PubMed  Google Scholar 

  9. Liyanage KE, Burnett JR, Hooper AJ, van Bockxmeer FM. Familial hypercholesterolemia: epidemiology, Neolithic origins and modern geographic distribution. Crit Rev Clin Lab Sci. 2011;48:1–18.

    Article  CAS  PubMed  Google Scholar 

  10. Goldstein JL, Schrott HG, Bierman EL. Hyperlipidemia in coronary heart disease and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest. 1973;52:1544–68.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  11. Stone NJ, Levy RI, Fredrickson DS, Verter J. Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia. Circulation. 1974;1(49):476–88.

    Article  Google Scholar 

  12. Macchiaiolo M, Gagliardi MG, Toscano A, Guccione P, Bartuli A. Homozygous familial hypercholesterolaemia. Lancet. 2012;379:1330.

    Google Scholar 

  13. Veerkamp MJ. Diagnosis of familial combined hyperlipidemia based on lipid phenotype expression in 32 families: results of a 5-year follow-up study. Arterioscler Thromb Vasc Biol. 2002;1(22):274–82.

    Article  Google Scholar 

  14. Ayyobi AF, Brunzell JD. Lipoprotein distribution in the metabolic syndrome, type 2 diabetes mellitus, and familial combined hyperlipidemia. Am J Cardiol. 2003;92:27–33.

    Article  Google Scholar 

  15. Gaddi A, Cicero a FG, Odoo FO, Poli AA, Paoletti R. Practical guidelines for familial combined hyperlipidemia diagnosis: an up-date. Vasc Health Risk Manag. 2007;3:877–86.

    Google Scholar 

  16. De Graaf J, Stalenhoef AF. Defects of lipoprotein metabolism in familial combined hyperlipidaemia. Curr Opin Lipidol. 1998;9:189–96.

    Article  PubMed  Google Scholar 

  17. Li S, Chen W, Srinivasan SR, Xu J, Berenson GS. Relation of childhood obesity/cardiometabolic phenotypes to adult cardiometabolic profile: the Bogalusa Heart Study. Am J Epidemiol. 2012;1(176 Suppl):S142–9.

    Article  Google Scholar 

  18. Soutar AK, Naoumova RP, Traub LM. Genetics, clinical phenotype, and molecular cell biology of autosomal recessive hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2003;1(23):1963–70.

    Article  Google Scholar 

  19. Lütjohann D, von Bergmann K. Phytosterolaemia: diagnosis, characterization and therapeutical approaches. Ann Med. 1997;29:181–4.

    Article  PubMed  Google Scholar 

  20. Weiss R, Dziura J, Burgert TS, Tamborlane WV, Taksali SE, Yeckel CW, et al. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med. 2004;3(350):2362–74.

    Article  Google Scholar 

  21. Kusters DM, de Beaufort C, Widhalm K, Guardamagna O, Bratina N, Ose L, et al. Paediatric screening for hypercholesterolaemia in Europe. Arch Dis Child. 2012;97:272–6.

    Article  CAS  PubMed  Google Scholar 

  22. Watts GF, Sullivan DR, Poplawski N, van Bockxmeer F, Hamilton-Craig I, Clifton PM, et al. Familial hypercholesterolaemia: a model of care for Australasia. Atheroscler Suppl. 2011;12:221–63.

    Article  PubMed  Google Scholar 

  23. Griffin TC, Christoffel KK, Binns HJ, McGuire PA. Family history evaluation as a predictive screen for childhood hypercholesterolemia, Pediatric Practice Research Group. Pediatrics. 1989;84:365–73.

    CAS  PubMed  Google Scholar 

  24. Umans-Eckenhausen MA, Defesche JC, Sijbrands EJ, Scheerder RL, Kastelein JJ. Review of first 5 years of screening for familial hypercholesterolaemia in The Netherlands. Lancet. 2001;357:165–8.

    Google Scholar 

  25. Huijgen R, Kindt I, Verhoeven SBJ, Sijbrands EJG, Vissers MN, Kastelein JJP, et al. Two years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterol-lowering treatment but a minority reaches treatment goal. PLoS One. 2010;5:e9220.

    Article  PubMed Central  PubMed  Google Scholar 

  26. Avis HJ, Kusters DM, Vissers MN, Huijgen R, Janssen TH, Wiegman A, et al. Follow-up of children diagnosed with familial hypercholesterolemia in a national genetic screening program. J Pediatr. 2012;161:99–103.

    Article  PubMed  Google Scholar 

  27. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics. 2011;128(Suppl):S213–56.

  28. Haney EM, Huffman LH, Bougatsos C, Freeman M, Steiner RD, Nelson HD. Screening and treatment for lipid disorders in children and adolescents: systematic evidence review for the US Preventive Services Task Force. Pediatrics. 2007;120:e189–214.

    Article  PubMed  Google Scholar 

  29. Schroeder AR, Redberg RF. Cholesterol screening and management in children and young adults should start early—no! Clin Cardiol. 2012;35:665–8.

    Article  PubMed  Google Scholar 

  30. Gillman MW, Daniels SR. Is universal pediatric lipid screening justified? JAMA. 2012;307:259–60.

  31. Psaty BM, Rivara FP. Universal screening and drug treatment of dyslipidemia in children and adolescents. JAMA. 2012;18(307):257–8.

    Google Scholar 

  32. Wald DS, Bestwick JP, Wald NJ. Child-parent screening for familial hypercholesterolaemia: screening strategy based on a meta-analysis. BMJ. 2007;22(335):599.

    Article  Google Scholar 

  33. Friedman LA, Morrison J a, Daniels SR, McCarthy WF, Sprecher DL. Sensitivity and specificity of pediatric lipid determinations for adult lipid status: findings from the Princeton Lipid Research Clinics Prevalence Program Follow-up Study. Pediatrics. 2006;118:165–72.

    Google Scholar 

  34. Obarzanek E, Kimm SYS, Barton BA, Van Horn L, Kwiterovich Jr PO, Simons-Morton DG, et al. Long-term safety and efficacy of a cholesterol-lowering diet in children with elevated low-density lipoprotein cholesterol: seven-year results of the Dietary Intervention Study in Children (DISC). Pediatrics. 2001;107:256–64.

    Google Scholar 

  35. Niinikoski H, Lagström H, Jokinen E, Siltala M, Rönnemaa T, Viikari J, et al. Impact of repeated dietary counseling between infancy and 14 years of age on dietary intakes and serum lipids and lipoproteins: the STRIP study. Circulation. 2007;28(116):1032–40.

    Article  Google Scholar 

  36. Pahkala K, Heinonen OJ, Simell O, Viikari JS, Rönnemaa T, Niinikoski H, et al. Association of physical activity with vascular endothelial function and intima-media thickness. Circulation. 2011;124:1956–63.

    Google Scholar 

  37. Pahkala K, Heinonen OJ, Lagström H, Hakala P, Hakanen M, Hernelahti M, et al. Clustered metabolic risk and leisure-time physical activity in adolescents: effect of dose? Br J Sports Med. 2012;46:131–7.

    Article  PubMed  Google Scholar 

  38. Erhardt L. Cigarette smoking: an undertreated risk factor for cardiovascular disease. Atherosclerosis. 2009;205:23–32.

    Article  CAS  PubMed  Google Scholar 

  39. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;8(366):1267–78.

    Google Scholar 

  40. Versmissen J, Oosterveer DM, Yazdanpanah M, Defesche JC, Basart DCG, Liem AH, et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ. 2008;337:a2423.

    Google Scholar 

  41. Avis HJ, Vissers MN, Stein EA, Wijburg FA, Trip MD, Kastelein JJP, et al. A systematic review and meta-analysis of statin therapy in children with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2007;27:1803–10.

    Google Scholar 

  42. Lecarpentier E, Morel O, Fournier T, Elefant E, Chavatte-Palmer P, Tsatsaris V. Statins and pregnancy: between supposed risks and theoretical benefits. Drugs. 2012;16(72):773–88.

    Article  Google Scholar 

  43. Kusters DM, Lahsinoui HH, van de Post JAM, Wiegman A, Wijburg FA, Kastelein JJP, et al. Statin use during pregnancy: a systematic review and meta-analysis. Expert Rev Cardiovasc Ther. 2012;10:363–78.

    Article  CAS  PubMed  Google Scholar 

  44. Rodenburg J, Vissers MN, Wiegman A, van Trotsenburg a SP, van der Graaf A, de Groot E, et al. Statin treatment in children with familial hypercholesterolemia: the younger, the better. Circulation. 2007;116:664–8.

  45. West RJ, Lloyd JK, Leonard JV. Long-term follow-up of children with familial hypercholesterolaemia treated with cholestyramine. Lancet. 1980;25(2):873–5.

    Article  Google Scholar 

  46. Perry CM. Colesevelam: in pediatric patients with heterozygous familial hypercholesterolemia. Paediatr Drugs. 2010;1(12):133–40.

    Article  Google Scholar 

  47. Stein EA, Marais AD, Szamosi T, Raal FJ, Schurr D, Urbina EM, et al. Colesevelam hydrochloride: efficacy and safety in pediatric subjects with heterozygous familial hypercholesterolemia. J Pediatr. 2010;156:231–6.e1–3.

    Google Scholar 

  48. Dujovne CA, Ettinger MP, McNeer JF, Lipka LJ, LeBeaut AP, Suresh R, et al. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol. 2002;15(90):1092–7.

    Article  Google Scholar 

  49. Knopp R. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J. 2003;24:729–41.

    Article  CAS  PubMed  Google Scholar 

  50. Clauss S, Wai K-M, Kavey R-EW, Kuehl K. Ezetimibe treatment of pediatric patients with hypercholesterolemia. J Pediatr. 2009;154:869–72.

    Article  CAS  PubMed  Google Scholar 

  51. Van der Graaf A, Cuffie-Jackson C, Vissers MN, Trip MD, Gagné C, Shi G, et al. Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia. J Am Coll Cardiol. 2008;21(52):1421–9.

    Article  Google Scholar 

  52. Pijlman AH, Huijgen R, Verhagen SN, Imholz BPM, Liem AH, Kastelein JJP, et al. Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands. Atherosclerosis. 2010;209:189–94.

    Google Scholar 

  53. Stein EA, Gipe D, Bergeron J, Gaudet D, Weiss R, Dufour R, et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet. 2012;380:29–36.

    Google Scholar 

  54. Roth EM, McKenney JM, Hanotin C, Asset G, Stein EA. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med. 2012;367:1891–900.

    Google Scholar 

  55. Raal FJ, Santos RD, Blom DJ, Marais AD, Charng M-J, Cromwell WC, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375:998–1006.

    Google Scholar 

  56. McGowan MP, Tardif J-C, Ceska R, Burgess LJ, Soran H, Gouni-Berthold I, et al. Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy. PLoS One. 2012;7:e49006.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  57. Cuchel M, Meagher EA, du Toit Theron H, Blom DJ, Marais AD, Hegele RA, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet. 2013;381:40–6.

  58. Thompson GR. Recommendations for the use of LDL apheresis. Atherosclerosis. 2008;198:247–55.

    Article  CAS  PubMed  Google Scholar 

  59. Stefanutti C, Julius U. Lipoprotein apheresis: state of the art and novelties. Atheroscler Suppl. 2013;14:19–27.

    Google Scholar 

  60. Palcoux J-B, Atassi-Dumont M, Lefevre P, Hequet O, Schlienger J-L, Brignon P, et al. Low-density lipoprotein apheresis in children with familial hypercholesterolemia: follow-up to 21 years. Ther Apher Dial. 2008;12:195–201.

    Article  CAS  PubMed  Google Scholar 

  61. Græsdal A, Bogsrud MP, Holven KB, Nenseter MS, Narverud I, Langslet G, et al. Apheresis in homozygous familial hypercholesterolemia: the results of a follow-up of all Norwegian patients with homozygous familial hypercholesterolemia. J Clin Lipidol. 2012;6:331–9.

    Article  PubMed  Google Scholar 

Download references

Conflicts of interest

No external funding was used in the preparation of this manuscript. JJPK is a consultant to, and has received honoraria from, Amgen, Sanofi Aventis, Regeneron, Eli Lilly, Genzyme, Isis Pharmaceuticals, Aegerion, Omthera, AstraZeneca, Pfizer, MSD, and Atheronova. MJAMB, BAH, and AW have no conflicts that might be relevant to the content of this review.

Author information

Authors and Affiliations

  1. Academic Medical Center, Department of Vascular Medicine, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands

    Marjet J. A. M. Braamskamp & John J. P. Kastelein

  2. Academic Medical Center, Department of Pediatrics, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands

    Marjet J. A. M. Braamskamp & Albert Wiegman

  3. Academic Medical Center, Clinical Epidemiology, Biostatistics and Bioinformatics, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands

    Barbara A. Hutten

Authors
  1. Marjet J. A. M. Braamskamp
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Barbara A. Hutten
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Albert Wiegman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. John J. P. Kastelein
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marjet J. A. M. Braamskamp.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Braamskamp, M.J.A.M., Hutten, B.A., Wiegman, A. et al. Management of Hypercholesterolemia in Children. Pediatr Drugs 16, 105–114 (2014). https://doi.org/10.1007/s40272-013-0060-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40272-013-0060-2

Keywords

Search

Navigation